BG104338A - Composition of lipid-reducing forms - Google Patents

Composition of lipid-reducing forms

Info

Publication number
BG104338A
BG104338A BG104338A BG10433800A BG104338A BG 104338 A BG104338 A BG 104338A BG 104338 A BG104338 A BG 104338A BG 10433800 A BG10433800 A BG 10433800A BG 104338 A BG104338 A BG 104338A
Authority
BG
Bulgaria
Prior art keywords
lipid
reducing
composition
smelt
time
Prior art date
Application number
BG104338A
Other languages
Bulgarian (bg)
English (en)
Inventor
Lieven Baert
Geert Verreck
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of BG104338A publication Critical patent/BG104338A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
BG104338A 1997-11-03 2000-04-14 Composition of lipid-reducing forms BG104338A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97203407 1997-11-03
PCT/EP1998/006998 WO1999022738A1 (en) 1997-11-03 1998-10-27 Compositions of lipid lowering agents

Publications (1)

Publication Number Publication Date
BG104338A true BG104338A (en) 2000-12-29

Family

ID=8228898

Family Applications (1)

Application Number Title Priority Date Filing Date
BG104338A BG104338A (en) 1997-11-03 2000-04-14 Composition of lipid-reducing forms

Country Status (20)

Country Link
US (1) US6342245B1 (xx)
EP (1) EP1028730B1 (xx)
JP (1) JP2001521899A (xx)
KR (2) KR20010023661A (xx)
CN (1) CN1278175A (xx)
AR (1) AR013739A1 (xx)
AT (1) ATE216238T1 (xx)
AU (1) AU746890B2 (xx)
BG (1) BG104338A (xx)
BR (1) BR9814109A (xx)
CA (1) CA2307097A1 (xx)
DE (1) DE69804994D1 (xx)
EE (1) EE200000186A (xx)
HU (1) HUP0004139A3 (xx)
NO (1) NO20002279L (xx)
NZ (1) NZ503413A (xx)
PL (1) PL340305A1 (xx)
SK (1) SK5972000A3 (xx)
WO (1) WO1999022738A1 (xx)
ZA (1) ZA989997B (xx)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE444060T1 (de) 2001-06-22 2009-10-15 Pfizer Prod Inc Pharmazeutische zusammensetzungen enthaltend dispersionen aus arzneistoffen und neutralen polymeren
US20030059487A1 (en) * 2001-09-21 2003-03-27 Niazi Sarfaraz K. Composition and method for the treatment of hypercholesterolemia and hyperlipidemia in mammals
US20040220240A1 (en) * 2001-11-28 2004-11-04 Pellegrini Cara A. Method of increasing the extent of absorption of tizanidine
US6455557B1 (en) * 2001-11-28 2002-09-24 Elan Pharmaceuticals, Inc. Method of reducing somnolence in patients treated with tizanidine
NZ546183A (en) * 2003-09-26 2011-04-29 Alza Corp Controlled release formulations exhibiting an ascending rate of release
ATE504288T1 (de) * 2003-09-26 2011-04-15 Alza Corp Oros-push-stick für die kontrollierte abgabe von wirkstoffen
JP5563731B2 (ja) * 2003-09-26 2014-07-30 アルザ・コーポレーシヨン オピオイドおよび非オピオイド鎮痛薬の制御放出製剤
JP4919801B2 (ja) * 2003-09-26 2012-04-18 アルザ・コーポレーシヨン 高い薬剤配合量を提供する薬剤コーティング及びそれを提供する方法
CN101664411A (zh) 2003-11-14 2010-03-10 味之素株式会社 苯丙氨酸衍生物的固体分散体或固体分散体医药制剂
WO2005097131A2 (en) * 2004-04-09 2005-10-20 Janssen Pharmaceutica N.V. Intermittent dosing regimen for the treatment of overweight with mtp-inhibitors
WO2005117834A1 (en) * 2004-05-27 2005-12-15 Janssen Pharmaceutica N.V. Solid dispersions of a basic drug compound and a polymer containing acidic groups
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
KR100582347B1 (ko) * 2004-12-30 2006-05-22 한미약품 주식회사 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법
CA2609783A1 (en) * 2005-05-27 2006-12-07 Pfizer Products Inc. Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss
US20090028938A1 (en) * 2005-08-08 2009-01-29 Abbott Gmbh & Co. Kg Dosage forms with improved bioavailability
EP1938804A1 (en) * 2006-12-22 2008-07-02 Novartis AG Pharmaceutical formulation comprising neurokinin antagonist
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
WO2010143199A1 (en) 2009-06-11 2010-12-16 Suven Nishtaa Pharma Private Limited Solid lipid dispersion for aqueous solubility enhancement of poorly water soluble drugs

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO118715B1 (ro) * 1994-10-27 2003-09-30 Janssen Pharmaceutica Nv Inhibitori ai sintezei apolipoproteinei-b
US5521186A (en) * 1994-10-27 1996-05-28 Janssen Pharmaceutica N.V. Apolipoprotein-β synthesis inhibitors

Also Published As

Publication number Publication date
EP1028730A1 (en) 2000-08-23
AU1157699A (en) 1999-05-24
WO1999022738A1 (en) 1999-05-14
NZ503413A (en) 2001-06-29
SK5972000A3 (en) 2000-12-11
KR20010023661A (ko) 2001-03-26
US6342245B1 (en) 2002-01-29
PL340305A1 (en) 2001-01-29
DE69804994D1 (de) 2002-05-23
BR9814109A (pt) 2000-10-03
HUP0004139A3 (en) 2002-03-28
JP2001521899A (ja) 2001-11-13
NO20002279D0 (no) 2000-04-28
NO20002279L (no) 2000-04-28
ATE216238T1 (de) 2002-05-15
KR20010023729A (ko) 2001-03-26
EP1028730B1 (en) 2002-04-17
AR013739A1 (es) 2001-01-10
HUP0004139A2 (hu) 2002-02-28
EE200000186A (et) 2001-04-16
CN1278175A (zh) 2000-12-27
AU746890B2 (en) 2002-05-02
CA2307097A1 (en) 1999-05-14
ZA989997B (en) 2000-05-02

Similar Documents

Publication Publication Date Title
BG104338A (en) Composition of lipid-reducing forms
EA200100024A1 (ru) Состав таблетки с делавирдином
MX9601069A (es) Nuevas pirido /3,2-e/pirazinonas con efecto antiasmatico y procedimiento para su preparacion.
MY123827A (en) Antifungal compositions with improved bioavailability
AU1339095A (en) Laxative compositions containing bulk fiber and dioctyl sulfosuccinate
NO20012529D0 (no) Dispersjoner av silylterminerte polymerer med höyt faststoffinnhold samt fremstilling og anvendelse derav
BG104819A (en) Substituted indolealkanoic acids
CA2253797A1 (en) Luminous or fluorescent artificial stone composition
BG102215A (en) Compounds and pharmaceutical compositions containing them
NZ510254A (en) Novel composition and use
AU2002221702A1 (en) Pharmaceutical compositions
BR9713952A (pt) Composição de moldagem de polìmero, e, artigo de formação termoplástica.
MY120550A (en) Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-ols, processes for preparing them and their use as pharmaceutical compositions.
EP0939104A3 (en) Rubber composition
BG104910A (en) Novel 1,2,5-trisubstituted 1,2-dihydroindazol-3-ones with anti-asthmatic, antiallergic, anti-inflammatory, immuno-modulating and neuro-protective effect, method for the production and use thereof as a medicament
AU8595791A (en) Galactomannan derivatives for coating or embedding medicinally active substances
AU5277396A (en) Hydraulic cement
AU5493298A (en) Stabilized pharmaceutical compositions and process for the preparation thereof
BG103412A (en) Stabilized pharmaceutical compositions based on chinupristine and dalfopristine and their preparation
TR200001384T2 (tr) Ateroskleroza bağlı arteryel-trombotik komplikasyonların önlenmesinde ketolitlerin kullanımı.
DE69313634T2 (de) Elastosole sowie deren herstellung, verwendung und produkte
AU2496288A (en) Poly-1-butene resin composition and water-proof sheet produced from the composition
BG104222A (en) Novel carboxylic acid derivatives, their production and their use as mixed eta/etb endothelin-receptor antagonists
PL311763A1 (en) Useful application of lacquer wastes, lacquer coagulum and solid substances containing lacquer wastes
AU5024596A (en) Cinnamoyl-c-glycoside chromone isolated from aloe barbadensis